Rokit Healthcare, Inc.

As of June 30, 2026, Rokit Healthcare, Inc. carries a market capitalization of 706.22B, placing it among publicly traded companies globally. Its enterprise value stands at 668.53B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Rokit Healthcare, Inc. has 15.69M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 20.20, and the price-to-book ratio stands at 104.30.

These figures are as of June 30, 2026. The EV/Sales ratio of 20.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 668.53B versus a market cap of 706.22B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Rokit Healthcare, Inc. maintains a current ratio of 0.89, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 379.68, indicating elevated leverage, while an interest coverage ratio of -2.97 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Rokit Healthcare, Inc. posted a negative return on equity (ROE) of -166.42, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -19.29, reflecting losses generated across the asset base. The company generates approximately 368.69M in revenue per employee across its workforce of 89.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.81 indicates how many times Rokit Healthcare, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Rokit Healthcare, Inc. recorded 885.21M in income tax expense. The company reported a pretax loss of -11.81B and -12.69B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Rokit Healthcare, Inc.'s stock has declined approximately 54.85% over the past 52 weeks. The 50-day moving average sits at 27,165.60, while the 200-day moving average is 58,278.65.

Over the twelve months ended June 30, 2026, Rokit Healthcare, Inc. generated 32.81B in revenue and converted that into -12.69B in net income, yielding earnings per share of -861.79. EBITDA reached -14.35B, while operating income came in at -14.98B.

As of June 30, 2026, Rokit Healthcare, Inc. holds 63.16B in cash and equivalents against 25.52B in total debt, resulting in a net debt position of 4.87B. Total book value stands at 6.77B, with working capital of -10.72B providing operational flexibility.

Rokit Healthcare, Inc. produced -25.76B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.01B in capital expenditures, free cash flow totaled -26.77B - equivalent to -1,817.55 per share.

Over the twelve months ended June 30, 2026, Rokit Healthcare, Inc. posted a gross margin of 48.61, reflecting its pricing power and cost economics. The operating margin of -45.64 and net profit margin of -38.67 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.04: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -13.51, meaning Rokit Healthcare, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Rokit Healthcare, Inc. has an Altman Z-Score of 2.31, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.